The drugs insurance companies are fighting hardest to avoid covering in 2026 fall into three clear categories: GLP-1 weight loss medications like Wegovy and Zepbound, expensive brand-name biologics like Humira and Stelara, and high-cost medications now subject to Medicare price negotiations under the Inflation Reduction Act. Over 12 million people lost commercial insurance coverage for Wegovy in 2026 alone, and more than 109 million Americans have no insurance coverage whatsoever for Zepbound after CVS Caremark removed it from their standard formulary in July 2025. These are not obscure specialty drugs — they are medications millions of people depend on daily.
For anyone managing a chronic condition, caring for an aging parent with dementia, or simply trying to stay on top of their own brain health, the shifting insurance landscape has real consequences. Medications that affect cardiovascular health, diabetes management, and inflammation all play indirect but meaningful roles in cognitive decline and dementia risk. This article breaks down which drugs are being dropped or restricted, why insurers are making these moves, how Medicare’s new negotiating power is reshaping the market, and what patients and caregivers can actually do about it.
Table of Contents
- Which Drugs Are Insurance Companies Refusing to Cover for Weight Loss?
- Why Are Brand-Name Biologics Being Dropped from Formularies?
- How Medicare Drug Price Negotiations Are Reshaping Coverage
- What Can Patients Do When Their Medication Coverage Is Denied?
- The Prior Authorization Crisis and Its Hidden Costs
- The Shrinking Medicare Drug Plan Market
- Where Drug Coverage Is Headed in 2027 and Beyond
- Conclusion
- Frequently Asked Questions
Which Drugs Are Insurance Companies Refusing to Cover for Weight Loss?
GLP-1 receptor agonists — sold under brand names like Wegovy, Zepbound, Ozempic, and Mounjaro — have become the most aggressively restricted class of drugs in the American insurance market. Blue Cross Blue Shield announced that starting January 1, 2026, its standard plans will not cover GLP-1 medications prescribed for weight loss, though coverage remains for diabetes. Pennsylvania Medicaid followed a similar path, ending coverage of GLP-1s for weight loss for adults 21 and older as of the same date. The result is that over 41 million people now have no commercial coverage for Wegovy, and the uncovered population for Zepbound jumped from 51 percent to 56 percent of commercially insured Americans. Even when these medications are prescribed for their original, FDA-approved purpose — managing Type 2 diabetes — insurers still throw up barriers.
Prior authorization or step therapy requirements are applied 78 percent of the time for Mounjaro and 81 percent of the time for Ozempic, according to formulary tracking data. Step therapy means a patient must first try and fail on a cheaper medication before the insurer will approve the one their doctor actually prescribed. For someone with poorly controlled blood sugar, those delays carry real health risks, including increased likelihood of cardiovascular events and, emerging research suggests, accelerated cognitive decline. Employers are also pulling back. Surveys show that companies offering health benefits found GLP-1 usage was higher than expected, and many are now considering scaling back coverage to manage runaway prescription drug costs. The concern is not whether these drugs work — the clinical evidence is strong — but whether anyone can afford to keep paying for them at current prices.
Why Are Brand-Name Biologics Being Dropped from Formularies?
The second major battleground involves brand-name biologics, where the three largest pharmacy benefit managers in the country have made an unprecedented coordinated move. All three major PBMs — CVS Caremark, UnitedHealth’s OptumRx, and Cigna’s Express Scripts — have largely removed brand Humira from their 2026 formularies, replacing it with private-label biosimilars produced by their own subsidiaries: Cordavis (CVS), Nuvaila (UnitedHealth), and Quallent (Cigna). This is not simply a switch to a cheaper equivalent. These PBMs are steering patients toward products they themselves profit from manufacturing. Stelara, used to treat conditions like Crohn’s disease and psoriasis, is following a similar path.
The brand’s IV formulation was removed from formularies effective January 1, 2026, and the subcutaneous version is being phased out by July 1, 2026, in favor of biosimilars. Entresto, a heart failure medication, has also been dropped by most major Medicare plans in North Carolina after a generic alternative gained approval in July 2025. However, if you are currently stable on a brand-name biologic, switching is not always straightforward. While biosimilars are clinically similar, some patients experience different side effect profiles or subtle differences in efficacy. The FDA considers them interchangeable, but your doctor may have medical reasons for keeping you on the original. If your insurer forces a switch and you experience problems, you have the right to file an exception request — though the process can take weeks, and approval is not guaranteed.
How Medicare Drug Price Negotiations Are Reshaping Coverage
The Inflation Reduction Act gave Medicare the power to negotiate prices on high-cost drugs for the first time, and the results from the first round are significant. Ten drugs were subject to negotiation for 2026: Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and NovoLog/Fiasp. The negotiated discounts range from 38 percent to 79 percent off list prices. Januvia, a diabetes drug, dropped 79 percent — from $527 to $113 for a 30-day supply. Eliquis, a blood thinner taken by millions of Americans including many with atrial fibrillation, dropped 56 percent from $521 to $231.
These price cuts are estimated to save Medicare beneficiaries $1.5 billion in annual out-of-pocket costs and save the Medicare program itself $6 billion per year. For dementia caregivers managing a loved one’s medications — many of whom take blood thinners, diabetes drugs, or heart failure treatments alongside their cognitive care regimen — this represents meaningful financial relief. A patient on both Eliquis and Januvia could see their monthly drug costs drop by several hundred dollars. The broader effect, though, is that drugmakers are responding to these forced discounts by shifting costs elsewhere. Some manufacturers have begun raising prices on drugs not yet subject to negotiation, and insurers are using the new pricing landscape as justification to tighten formularies across the board.
What Can Patients Do When Their Medication Coverage Is Denied?
The first step when your insurer denies coverage is understanding whether the denial is based on formulary exclusion, prior authorization requirements, or step therapy protocols — because the appeal process differs for each. For formulary exclusions, you can request a formulary exception, which requires your doctor to submit a letter explaining why the excluded drug is medically necessary and why alternatives are insufficient. According to federal data on Medicare Advantage plans, 67 percent of prior authorization denials are overturned on appeal, meaning most patients who fight back win. The tradeoff is time. Filing appeals, gathering documentation, and waiting for decisions can take weeks or even months.
For a caregiver managing someone with dementia, that delay can mean missed doses of critical medications — diabetes drugs, blood thinners, or anti-inflammatory biologics — during a period when consistency matters enormously. Patient advocacy organizations like the Medicare Rights Center and state health insurance assistance programs (SHIPs) can help navigate the process, but the burden still falls disproportionately on the people least equipped to handle it. It is also worth checking manufacturer assistance programs directly. Most major drugmakers, including the makers of Wegovy, Humira, and Eliquis, offer copay cards or patient assistance programs for people who lose coverage. These programs have income limits and eligibility requirements, but they can bridge the gap while you fight an appeal.
The Prior Authorization Crisis and Its Hidden Costs
Prior authorization — the requirement that your insurer approve a medication before your pharmacy can fill it — has expanded dramatically. A 2024 American Medical Association survey found that 92 percent of physicians reported prior authorization requirements had increased over the previous five years. In oncology, the numbers are particularly stark: 95 percent of branded cancer drug prescriptions were subject to prior authorization in 2022. This is not a targeted tool being used judiciously. It has become a blanket policy applied to nearly everything that costs money. The hidden cost is clinical.
When a doctor prescribes a medication and the patient cannot start it for two or three weeks while paperwork is processed, conditions worsen. For someone with early-stage cognitive decline taking a cardiovascular medication that protects brain health, or a diabetic whose poorly managed blood sugar accelerates neurodegeneration, those delays are not administrative inconveniences — they are medical events. In Medicare Advantage plans, 6 percent of prior authorization requests are outright denied, compared to 13 percent in Medicaid. But even a 6 percent denial rate, applied across millions of prescriptions, translates to enormous numbers of people going without prescribed treatment. Insurers are also quietly making generics harder to access. By splitting generic drugs into preferred and non-preferred tiers, they push complex generics — certain antidepressants, extended-release formulations, and specialty generics — to higher cost-sharing tiers. A generic that should cost $10 might land on a tier where the patient pays $50 or more, undermining the entire point of generic availability.
The Shrinking Medicare Drug Plan Market
The number of standalone Medicare prescription drug plans dropped 22 percent between 2025 and 2026, falling from 464 plans to just 360. Medicare Advantage plans with drug coverage also declined by 9 percent. For seniors and their caregivers, this means fewer choices during open enrollment, less competition among plans, and in many regions, only one or two viable options.
When there are fewer plans competing for enrollees, there is less incentive to offer generous formularies. This consolidation matters especially for people managing multiple chronic conditions alongside dementia. A plan that covers your cholinesterase inhibitor but excludes your blood thinner or heart failure medication forces impossible choices. During each year’s Medicare open enrollment period, it is critical to use the Medicare Plan Finder tool to compare formularies drug by drug — not just look at premiums and star ratings.
Where Drug Coverage Is Headed in 2027 and Beyond
The next round of Medicare drug price negotiations will target additional high-cost medications, and the political pressure to expand the program is significant from both parties, though for different reasons. At the same time, more biosimilars are entering the market for drugs like Stelara and Humira, which should eventually push prices down through competition — assuming PBMs do not simply pocket the savings through their vertically integrated subsidiaries. For patients and caregivers focused on brain health, the practical outlook is mixed.
Drugs that manage the conditions most strongly linked to dementia risk — diabetes, hypertension, cardiovascular disease, and chronic inflammation — are precisely the categories where insurance coverage is most volatile right now. Staying informed about annual formulary changes, maintaining relationships with prescribers willing to fight prior authorization battles, and using every available appeal mechanism are no longer optional. They are essential parts of managing long-term health.
Conclusion
The drugs insurance companies are fighting hardest to avoid covering in 2026 — GLP-1 weight loss medications, brand-name biologics, and high-cost chronic disease treatments — share a common thread: they are expensive, widely prescribed, and directly relevant to the conditions that drive cognitive decline and dementia risk. With over 12 million people losing Wegovy coverage, all three major PBMs replacing brand Humira with their own biosimilars, and prior authorization requirements climbing to affect 92 percent of physicians’ practices, the system is actively making it harder for patients to access the medications their doctors prescribe. The most important step any patient or caregiver can take is to never accept a coverage denial as final.
With 67 percent of Medicare Advantage denials overturned on appeal, the odds favor persistence. Review your plan’s formulary before each enrollment period, ask your doctor to submit exception requests when needed, and explore manufacturer assistance programs as a bridge. The insurance landscape will keep shifting — but informed patients who advocate for themselves consistently get better outcomes.
Frequently Asked Questions
Can my doctor override an insurance company’s decision not to cover a drug?
Your doctor cannot directly override the decision, but they can submit a prior authorization request or formulary exception with clinical documentation explaining why the specific drug is medically necessary. In Medicare Advantage, 67 percent of denied prior authorizations are overturned on appeal, so the effort is often worthwhile.
If my insurer switches me from brand Humira to a biosimilar, is that safe?
The FDA considers approved biosimilars to be clinically interchangeable with their reference biologics. Most patients transition without issues. However, if you experience new side effects or a change in symptom control after switching, contact your doctor immediately — you may qualify for a medical exception to return to the brand-name version.
Are GLP-1 drugs like Ozempic still covered for diabetes?
Generally yes, but with significant restrictions. Prior authorization or step therapy is required 81 percent of the time for Ozempic and 78 percent of the time for Mounjaro, even when prescribed for Type 2 diabetes. The coverage bans primarily target weight loss indications.
How much will I save on Medicare-negotiated drugs in 2026?
Savings vary by drug. Januvia dropped 79 percent from $527 to $113 per month, and Eliquis dropped 56 percent from $521 to $231. Overall, the negotiated prices are expected to save Medicare beneficiaries $1.5 billion in annual out-of-pocket costs across the ten drugs included in the first round.
What should I do during Medicare open enrollment to protect my drug coverage?
Use the Medicare Plan Finder tool at medicare.gov to compare each plan’s formulary against your specific medication list. Do not rely on premiums or star ratings alone. Check whether your drugs are on a preferred tier, whether prior authorization is required, and whether any medications have been excluded from the formulary entirely.
